A5024647452- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Esophageal and GI Pathology
- Pediatric Hepatobiliary Diseases and Treatments
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Biliary and Gastrointestinal Fistulas
- Nutrition and Health in Aging
- Cancer Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- Oral health in cancer treatment
- Frailty in Older Adults
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research and Treatments
- Lymphatic System and Diseases
- GDF15 and Related Biomarkers
- Genetic and Kidney Cyst Diseases
- Intraperitoneal and Appendiceal Malignancies
Japanese Foundation For Cancer Research
2020-2025
Cancer Institute (WIA)
2020-2023
The Cancer Institute Hospital
2020
Kansai Rosai Hospital
2019
Abstract Background There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose this study was to evaluate the efficacy and tolerability modified FOLFIRINOX (mFFX) as a MPC investigate prognostic factors survival. Methods From 2015 2019, we retrospectively reviewed medical records consecutive patients receiving mFFX GnP therapy. Patients were treated every 2 weeks with (intravenous...
782 Background: Liquid biopsy offers an alternative to tissue specimens for comprehensive genetic profiling. However, circulating tumor DNA is sometimes insufficient detect genomic alterations in pancreatic cancer (PC). The detection rate of KRAS mutations was reportedly increased PC with liver metastasis. In contrast, the predictive value CA19-9 levels, timing liquid biopsy, or type detecting remains unclear. We investigated whether these factors could be PC. Methods: From September 2021...
Stenting against recurrent biliary obstruction (RBO) after placement of covered metal stent (CMS) for distal malignant (MBO) is still challenging. This study investigated the feasibility a novel laser-cut fully CMS with anti-reflux valve in patients MBO refractory to conventional CMS.Patients who underwent Duckbill-type (DMS) between June 2019 and May 2020 were included. Early complications, causes RBO including non-occlusion cholangitis, time (TRBO) evaluated. TRBO DMS was also compared...
Objective Anamorelin, a novel selective ghrelin receptor agonist, was approved in Japan for the treatment of cachexia pancreatic cancer (PC), albeit with limited evidence. This study evaluated efficacy and safety anamorelin PC examined impact extent weight loss on anamorelin. Methods We retrospectively investigated consecutive patients who received at our institution between June 2021 January 2022. Patients were divided into two groups: moderate-weight-loss group (5-10%) severe-weight-loss...
Abstract Background and study aims Self-expandable metallic stents (SEMS) are now widely used even for patients with borderline resectable (BR) pancreatic cancer (PC), as neoadjuvant therapy has become common. Therefore, we conducted this to evaluate safety of SEMS placement in the population including BR PC explore risk factors recurrent biliary obstruction (RBO), pancreatitis, cholecystitis. Patients methods We retrospectively investigated consecutive who received initial between January...
Abstract Objective With the introduction of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy for unresectable pancreatic cancer, erlotinib is now occasionally used as late-line therapy. This study investigates outcomes treatment with cancer. Methods We retrospectively analysed consecutive patients cancer treated third or later-line chemotherapy between March 2014 December 2020 in our hospital. Results A total 56 were included (third line/fourth later line = 42/14). All...
Outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with treated GnP first-line mFFX treatment between March 2015 2022 at our hospital. A total 103 included. Median overall survival (OS) from the start treatments was 14.9 months 7.2 months, respectively. progression-free (PFS) 3.6 months. Performance status, Glasgow score,...
Abstract We report a case of ruptured cystic artery pseudoaneurysm after self‐expandable metal stent placement for malignant biliary obstruction. A 78‐year‐old woman on palliative care chemotherapy unresectable pancreatic head cancer presented with obstructive jaundice. Imaging revealed dilated common bile duct and an enlarged gallbladder wall thickening. Endoscopic retrograde cholangiopancreatography was performed fully‐covered placed in the duct, leading to resolution She hematochezia 7...
Abstract Background Although the efficacy of neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC GS) has recently been reported in resectable pancreatic cancer, severe adverse events were frequently observed. Sarcopenia to be associated reduced antitumor response and toxicity several malignancies. The aim this study is evaluate impact body composition on short-term outcomes NAC GS cancer patients. Methods Clinicopathological data consecutive patients treated at our institution from...
Objective The coronavirus disease (COVID-19) pandemic has altered the delivery of medical care. present study evaluated impact COVID-19 on outcomes unresectable pancreatic cancer (PC) patients who received end-of-life
Abstract Background 10‐mm self‐expandable metal stents (SEMSs) are commonly used for preoperative biliary drainage in pancreatic cancer. However, smaller diameter SEMSs have attracted attention with the attempt to reduce stent‐related adverse events (AEs). Methods We retrospectively analyzed consecutive borderline resectable cancer patients who underwent neoadjuvant therapy and fully covered SEMS (FCSEMS) placement from April 2015 May 2023. The primary outcome was non‐event rate (NER), which...
Background/Aims: The optimal length of the uncovered portion partially covered self-expandable metal stents (PCSEMSs) used in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. This study investigated safety and efficacy PCSEMSs with different lengths, a focus on stent migration time to recurrent biliary obstruction (RBO).Methods: Outcomes patients undergoing EUS-HGS using 5-mm 20-mm portions at our institution from January 2016 December 2021 were compared.Results:...
Pancreatic cancer with lung oligometastasis may have favourable overall survival. The aim of this study was to evaluate outcomes pancreatic oligometastases including both synchronous and metachronous metastases.Consecutive patients metastasis treated at our institution between February 2015 December 2021 were identified from prospectively maintained database. Clinical characteristics compared analysed according the extent metastases. Predictors for survival using Cox proportional hazards...
To compare the treatment outcomes of gemcitabine with nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX; a combination fluorouracil, leucovorin, irinotecan, oxaliplatin) for metastatic pancreatic cancer.We retrospectively analyzed consecutive patients or recurrent cancer treated GnP mFFX as first-line chemotherapy between March 2014 December 2019 in our hospital. Treatment were compared using propensity score matching to adjust age, sex, performance status, carcinoembryonic antigen levels,...
Background. A higher Ki-67 labeling index is associated with a poorer prognosis in gastroenteropancreatic neuroendocrine neoplasms. It has also been proposed that the may increase during disease progression from primary site to metastatic sites. Although biopsy specimens are used measure index, heterogeneity lesions thought affect assessment of index. To overcome tumor heterogeneity, we evaluated variability between and hepatic metastases by analyzing only surgically resected specimens....
To compare the treatment outcomes of nanoliposomal-irinotecan (nal-IRI) plus fluorouracil and leucovorin (5-FU/LV) modified FOLFIRINOX (mFFX) as second-line after gemcitabine with nab-paclitaxel (GnP) for metastatic recurrent pancreatic cancer.We retrospectively analyzed consecutive patients or cancer treated nal-IRI 5-FU/LV mFFX first-line GnP between March 2014 October 2021 in our hospital. Patient characteristics, adverse events were extracted comparison.Two hundred sixteen included...